Jie Zhu
Shandong University of Traditional Chinese Medicine(CN)University of Electronic Science and Technology of China(CN)Fudan University(CN)AstraZeneca (Australia)(AU)Sichuan Cancer Hospital(CN)Hangzhou Hospital of Traditional Chinese Medicine(CN)AstraZeneca (Italy)(IT)AstraZeneca (Spain)(ES)Changzhou No.2 People's Hospital(CN)Changzhou Third People's Hospital(CN)Affiliated Hospital of Shandong University of Traditional Chinese Medicine(CN)Nanjing Medical University(CN)
Publications by Year
Research Areas
Liver physiology and pathology, Liver Disease Diagnosis and Treatment, MicroRNA in disease regulation, Hepatocellular Carcinoma Treatment and Prognosis, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Size-dependent cellular uptake efficiency, mechanism, and cytotoxicity of silica nanoparticles toward HeLa cells(2013)171 cited
- → Nanocomposite of MoS2 on ordered mesoporous carbon nanospheres: A highly active catalyst for electrochemical hydrogen evolution(2012)153 cited
- → MicroRNA‐101 suppresses liver fibrosis by targeting the TGFβ signalling pathway(2014)125 cited
- → H19/miR‐148a/USP4 axis facilitates liver fibrosis by enhancing TGF‐β signaling in both hepatic stellate cells and hepatocytes(2018)116 cited
- → The apoB100/apoAI ratio is independently associated with the severity of coronary heart disease: a cross sectional study in patients undergoing coronary angiography(2015)37 cited
- → The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma(2021)33 cited